| Full text | |
| Author(s): |
Magalhaes, Taciani de Almeida
[1]
;
de Sousa, Graziella Ribeiro
[1]
;
Cruzeiro, Gustavo Alencastro Veiga
[2]
;
Tone, Luiz Gonzaga
[1, 2]
;
Valera, Elvis Terci
[2]
;
Borges, Kleiton Silva
[2]
Total Authors: 6
|
| Affiliation: | [1] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Genet, Av Bandeirantes 3900, BR-14048900 Sao Paulo - Brazil
[2] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pediat, Av Bandeirantes 3900, BR-14048900 Sao Paulo - Brazil
Total Affiliations: 2
|
| Document type: | Review article |
| Source: | JOURNAL OF MOLECULAR MEDICINE-JMM; v. 98, n. 4 MAR 2020. |
| Web of Science Citations: | 0 |
| Abstract | |
Glioblastoma is the most common aggressive primary brain tumor. Standard care includes maximal safe surgical resection, radiation, and chemotherapy with temozolomide. However, the impact of this therapeutic approach on patient survival is disappointing and poor outcomes are frequently observed. Therefore, new therapeutic targets are needed to treat this potentially deadly tumor. Aurora kinases are one of today's most sought-after classes of therapeutic targets to glioblastoma therapy. They are a family of proteins composed of three members: Aurora-A, Aurora-B, and Aurora-C that play different roles in the cell division through regulation of chromosome segregation. Deregulation of these genes has been reported in glioblastoma and a progressive number of studies have shown that inhibition of these proteins could be a promising strategy for the treatment of this tumor. This review discusses the preclinical and early clinical findings on the potential use of the Aurora kinases as new targets for the treatment of glioblastoma. Key messages GBM is a very aggressive tumor with limited therapeutic options. Aurora kinases are a family of serine/threonine kinases implicated in GBM pathology. Aurora kinases are critical for glioblastoma cell growth, apoptosis, and chemoresistance. Inhibition of Aurora kinases has a synergistic or sensitizing effect with chemotherapy drugs, radiotherapy, or with other targeted molecules in GBM. Several Aurora kinase inhibitors are currently in clinical trials. (AU) | |
| FAPESP's process: | 17/06511-8 - Investigation of Smad2/3-YAP complex as a chemoresistant factor in TP53 |
| Grantee: | Gustavo Alencastro Veiga Cruzeiro |
| Support Opportunities: | Scholarships in Brazil - Post-Doctoral |
| FAPESP's process: | 16/19820-6 - Investigation of new therapeutic targets from transcriptional networks of genes of the mitotic spindle associated with embryonic developmental pathways in the ependymoma: focus on molecular subgroups of worst outcome |
| Grantee: | Taciani de Almeida Magalhães |
| Support Opportunities: | Scholarships in Brazil - Doctorate |
| FAPESP's process: | 18/23372-4 - Study of the effects of DNA demethylation on genes associated with developmental pathways in pediatric Ependymomas |
| Grantee: | Graziella Ribeiro de Sousa |
| Support Opportunities: | Scholarships in Brazil - Doctorate |